# US 2025/0145962 A1 · Compositions, systems, and methods relating to three-dimensional (3d) bioprinted liver tissue models

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145962 A1
- Document ID: US20250145962A1
- Status: Published application
- Kind: A1
- Application number: 18/695,063
- Filed: 2022-10-04
- Published: 2025-05-08
- Earliest claimed: 2021-10-05
- Assignees: University of Florida Research Foundation, Inc.; Merck Sharp & Dohme Corp.
- Applicants: University of Florida Research Foundation; Merck Sharp & Dohme Corp.
- Inventors: Thomas Ettor ANGELINI; Carolina Elizabeth ABRAHAN; Steven CHISOLM; Jon P. DOBSON; Clayton Elwood MATHEWS; Peter S. MCFETRIDGE; Glyn Daniel PALMER; Vignesh SUBRAMANIAM; Brent S. SUMERLIN; Andreas BAUDY; Brett HIGGINS
- Web page: https://patentgrep.com/patent/US20250145962A1

## CPC

- C12N 5/067: {Hepatocytes}
- C12N 5/0671: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- B33Y 70/00: Materials specially adapted for additive manufacturing
- C12M 21/08: {for producing artificial tissue or for ex-vivo cultivation of tissue (prostheses A61F2/00, grafts A61L27/00)}
- C12M 29/10: {Perfusion}
- C12N 5/069: {Vascular Endothelial cells}
- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2502/14: hepatocytes
- C12N 2502/28: Vascular endothelial cells
- C12N 2503/02: Drug screening
- C12N 2533/54: Collagen; Gelatin
- C12N 2535/10: Patterned coating
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B33Y: ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

Disclosed herein are compositions, systems, and methods relating to three-dimensional bioprinted tissue models, in particular liver tissue modes. Compositions, systems, and methods as described here provide for improved tissue models, thereby improving their utility for diagnostic, clinical, and research purposes. In certain aspects, tissue models as described herein exhibit gene expression profiles, enzymatic function, and enzyme/protein secretion comparable to in vivo organs.

## Claims

### Claim 1

A planar cellular composition, comprising hepatocytes and endothelial cells in a matrix material, wherein the hepatocytes and endothelial cells are present in a ratio of about 2:1 to 1:1 hepatocytes:endothelial cells.

### Claim 2 (depends on 1)

The planar cellular composition of claim 1, wherein the hepatocytes are primary cells.

### Claim 3 (depends on 1)

The planar cellular composition of claim 1, wherein the endothelial cells are vascular endothelial cells.

### Claim 4 (depends on 1)

The planar cellular composition of claim 1, wherein the hepatocytes and endothelial cells are present in a ratio of about 2:1 hepatocytes:endothelial cells.

### Claim 5 (depends on 1)

The planar cellular composition of claim 1, wherein the matrix material comprises collagen.

### Claim 6 (depends on 1)

The planar cellular composition of claim 1, wherein the planar cellular composition has at least one physical dimension between about 5 to 20 cells in thickness.

### Claim 7 (depends on 1)

The planar cellular composition of claim 1, wherein the planar composition has a circular or oval shape.

### Claim 8 (depends on 6)

The planar cellular composition of claim 6, wherein the circular or oval shape has a about 0.5 to 10 mm diameter, including about 1.5 to 2.5 mm in diameter.

### Claim 9 (depends on 1)

The planar cellular composition of claim 1, wherein the endothelial cells form one or more sinusoidal structures that are not organized into a network.

### Claim 10

A method of creating a planar cellular composition, comprising:
mixing hepatocytes, endothelial cells, and a matrix material in a cellular growth medium to form a cellular mixture, wherein the hepatocytes and endothelial cells are present in a ratio of about 15:10 to 20:15 hepatocytes:endothelial cells;
placing the cellular mixture in a support medium to form a planar cellular composition about 5 to 20 cells in thickness and about 0.5 to 10 mm diameter; and
culturing the cellular mixture under physiological growth conditions to produce the planar cellular composition.

### Claim at position 11

11-21. (canceled)

### Claim 22 (depends on 9)

A planar cellular composition produced according to the method of claim 9.

### Claim 23 (depends on 1)

A tissue culture system, comprising:
the planar cellular composition of claim 1 embedded in a support medium; and
a bioreactor.

### Claim 24 (depends on 23)

The system of claim 23, further comprising a cellular growth medium.

### Claim 25 (depends on 24)

The system of claim 24, wherein the cellular growth medium comprises hepatocyte growth factor (HGF) but does not comprise vascular endothelial growth factor (VEGF).

### Claim 26 (depends on 23)

The system of claim 23, wherein the bioreactor is a perfusion-enabled bioreactor.

### Claim 27 (depends on 23)

The system of claim 23, wherein support medium comprises polymeric packed microgel particles.

### Claim 28 (depends on 23)

The system of claim 23, wherein the support medium comprises poly-ethylene glycol (PEG) microparticles.

### Claim 29 (depends on 1)

A method for screening candidate agents, comprising contacting the candidate agent to the planar cellular composition of claim 1 and evaluating one or more properties of the planar cellular composition.

### Claim at position 20

30-32. (canceled)
